LY-2780301

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLY-2780301
Drug Alias NameLY-2780301LY-S6KAKT1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action70-kDa ribosomal protein S6 kinases inhibitors
Targets70-kDa ribosomal protein S6 kinases
Therapy Area/IndicationsNeoplasm MetastasisBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFranceSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesInstitut Paoli-Calmettes
Active IndicationsBreast Neoplasms
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A